Sangamo Earnings Reports

Sangamo Therapeutics reported a net loss of $23.4 million, a significant improvement from the prior year's $60.3 million. Revenue increased to $7.6 million, driven by new license agreements with Astellas and Genentech. Operating expenses declined due to cost reductions and restructuring efforts. The company continues to focus on its neurology pipeline and upcoming regulatory milestones.

Sangamo Therapeutics reported a net income of $10.7 million for Q3 2024, a significant turnaround from the $104.2 million net loss in Q3 2023. Revenues increased substantially due to the Genentech collaboration. The company also announced a clear regulatory path for its Fabry disease program and the submission of an IND application for a chronic neuropathic pain treatment.

Sangamo announced a global license agreement with Genentech, positive results from the Phase 3 AFFINE trial with Pfizer, and encouraging data from the Phase 1/2 STAAR study. The company's net loss was $36.1 million, and revenues were $0.3 million for the quarter.

Sangamo Therapeutics reported a net loss of $49.1 million for Q1 2024, compared to a net income of $21.1 million for the same period in 2023. Revenues decreased to $0.5 million from $158.0 million year-over-year, primarily due to the termination of collaboration agreements. The company's cash and cash equivalents totaled $54.4 million as of March 31, 2024.

Sangamo Therapeutics reported its Q4 and full year 2023 financial results, highlighting the prioritization of its neurology pipeline and progress with novel AAV capsid delivery technology. The company is seeking partnerships for its Fabry disease program and anticipates pivotal data read-out for its Hemophilia A collaboration with Pfizer in mid-2024.

Sangamo Therapeutics announced progress in its strategic transformation into a neurology-focused genomic medicine company, including restructuring of operations and workforce reduction. They are focusing on epigenetic regulation therapies and novel AAV capsid delivery technologies, while seeking partners for Fabry gene therapy and CAR-Treg cell therapy programs. Q3 2023 revenue was $9.4 million, and the net loss was $104.2 million, or $0.59 per share.

Sangamo Therapeutics reported a net loss of $114.5 million for Q2 2023, compared to a net loss of $43.2 million for the same period in 2022. The increase in net loss was primarily due to higher non-cash charges relating to impairment of indefinite-lived intangible assets and a decrease in revenues.

Sangamo Therapeutics announced a strategic pipeline prioritization and corporate restructuring, including a US workforce reduction of approximately 27%. The company is focusing on Nav 1.7 and Prion, Fabry Phase 3 readiness, and the TX200 CAR-Treg clinical study. First quarter revenues are estimated at $158.0 million, compared to $28.2 million for the same period in 2022. Cash, cash equivalents and marketable securities were $241.0 million as of March 31, 2023.

Sangamo Therapeutics reported fourth quarter 2022 revenues of $27.2 million and a net loss of $52.0 million, or $0.32 per share. The company highlighted progress in its Fabry disease, renal transplant rejection, sickle cell disease, and hemophilia A programs, and provided initial financial guidance for 2023.

Sangamo Therapeutics reported a net loss of $53.2 million, or $0.34 per share, for the third quarter ended September 30, 2022. Revenues for the quarter were $26.5 million. The company continued to advance its clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence.

Sangamo Therapeutics reported a net loss of $43.2 million, or $0.29 per share, for the second quarter of 2022. The company is advancing its clinical-stage programs and preparing to complete dosing of the first cohort in its TX200 program.

Sangamo Therapeutics reported a consolidated net loss of $44.0 million, or $0.30 per share, for the first quarter ended March 31, 2022. Revenues for the quarter were $28.2 million. The company continues to progress multiple programs through clinical development, including dosing the first patient in a study for kidney transplant rejection.

Sangamo Therapeutics reported a net loss of $37.5 million, or $0.26 per share, for the fourth quarter ended December 31, 2021. Revenues for the quarter were $28.0 million, compared to $25.8 million for the same period in 2020. The company is advancing its genomic medicines pipeline and has fully operational AAV and cell therapy manufacturing facilities.

Sangamo Therapeutics reported a net loss of $47.7 million, or $0.33 per share, for the third quarter ended September 30, 2021. Revenues for the quarter were $28.6 million. The company is advancing its gene therapy portfolio and has initiated planning for a Phase 3 Fabry disease clinical trial.

Sangamo reported a net loss of $47.2 million, or $0.33 per share, for the second quarter of 2021. Revenues increased to $27.9 million compared to $21.6 million for the same period in 2020, primarily due to collaboration agreements with Novartis and Biogen. Operating expenses also increased, driven by higher clinical and manufacturing supply expenses and increased headcount.

Sangamo Therapeutics reported a consolidated net loss of $45.9 million, or $0.32 per share, for the first quarter ended March 31, 2021. Revenues for the quarter were $26.3 million, primarily due to recognition of upfront license fees and research reimbursements from Biogen and Novartis collaborations.

Sangamo Therapeutics reported a consolidated net loss of $40.7 million for the fourth quarter ended December 31, 2020, compared to net income of $4.5 million for the same period in 2019. Revenues for the fourth quarter ended December 31, 2020 were $25.8 million, compared to $54.9 million for the same period in 2019. Cash, cash equivalents and marketable securities as of December 31, 2020 were $692.0 million, compared to $384.3 million as of December 31, 2019.

Sangamo Therapeutics reported a decrease in net loss attributable to Sangamo for the third quarter ended September 30, 2020, with revenues increasing compared to the same period in 2019. The company also highlighted clinical execution momentum across its portfolio and the completion of research activities in its ALS program partnered with Pfizer.

Sangamo Therapeutics reported a net loss of $35.9 million, or $0.26 per share, for the second quarter ended June 30, 2020. Revenues for the quarter were $21.6 million. The company's cash, cash equivalents, and marketable securities totaled $664.9 million as of June 30, 2020.

Sangamo reported a net loss of $42.9 million, or $0.37 per share, for the first quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $363.1 million as of March 31, 2020. They closed a collaboration agreement with Biogen, receiving $225 million in stock sale proceeds and an additional $125 million upfront license fee.

Sangamo Therapeutics reported a net income of $4.6 million for Q4 2019, a significant turnaround from the $18.7 million net loss in the same period of 2018. Revenue also increased to $54.9 million, driven by milestone payments from Pfizer and Sanofi.